Election 2020 | Life Sciences Roundtable: A Discussion on How the 2020 Election May Impact FDA-Regulated Companies

On November 20, Skadden presented a webinar titled “Election 2020 | Life Sciences Roundtable: A Discussion on How the 2020 Election May Impact FDA-Regulated Companies.” Skadden speakers included Washington, D.C. litigation head Jennifer Bragg and partner William (Bill) McConagha. Guest speakers included Charles Clapton, executive director, congressional affairs at Gilead Sciences, and Jeffrey Francer, senior vice president and general counsel at the Association for Accessible Medicines. Topics included potential changes in priorities at the U.S. Department of Health and Human Services, possible shifts within the U.S. Food and Drug Administration, and criminal and legislative developments, including under the False Claims Act and at the U.S. Department of Justice.